The E-cadherin expression vs. tumor cell proliferation paradox in endometrial cancer

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 5091-5096

  González Rodilla, Irene ^a   Aller, Laura ^a   Llorca, Javier ^b   Muñoz, Ana Belén ^a   Verna, Virginia ^a   Estévez, José ^a   Schneider, José ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

E cadherin; Endometrial carcinoma; Proliferation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CELL PROLIFERATION; ENDOMETRIUM CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; VERY ELDERLY;

E-CADHERIN; ENDOMETRIAL CARCINOMA; PROLIFERATION;

ADENOCARCINOMA, CLEAR CELL; CADHERINS; CARCINOMA, PAPILLARY; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891354610     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. González-Rodilla I, Verna V, Muñoz AB, Estévez J, Boix M and Schneider J: Expression of the apoptosis-related genes Bcl-2 and p53 in clinical samples from endometrial carcinoma patients. Anticancer Res 31: 4191-4194, 2011.
2. Singh M, Darcy KM, Brady WE, Clubwala R, Weber Z, Rittenbach JV, Akalin A, Whitney CW, Zaino R, Ramirez NC and Leslie KK: Cadherins, catenins and cell cycle regulators: Impact on survival in a Gynecologic Oncology group phase-II endometrial cancer trial. Gynecol Oncol 123: 320-328, 2011.
3. Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10-17, 1983.
4. Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105: 103-104, 2009.
5. Schneider J, Efferth T, Centeno MM, Mattern J, Rodríguez-Escudero F and Volm M: High rate of expression of multidrug resistance-associated P-glycoprotein in human endometrial carcinoma and normal endometrial tissue. Eur J Cancer 29A: 554-558, 1993.
6. Schneider J, Pollán M, Jiménez E, Marenbach K, Martínez N, Volm M, Marx D and Meden H: Nm23-H1 expression defines a high-risk subpopulation of patients with early-stage epithelial ovarian carcinoma. Br J Cancer 82: 1662-1670, 2000.
7. Mell LK, Meyer JJ, Tretiakova M, Khramtsov A, Gong C, Yamada SD, Montag AG and Mundt AJ: Prognostic significance of E-Cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res 10: 5546-5553, 2004.
8. Kim YT, Choi EK, Kim JW, Kim DK, Kim SH and Yang WI: Expression of E-Cadherin and alpha-,beta-, gamma-catenin proteins in endometrial carcinoma. Yonsei Med J 43: 701-711, 2002.